

DUAL GIP / GLP-1 RECEPTOR AGONIST · ONCE-WEEKLY INJECTION

TIRZE- PATIDE



The Next Generation of

Metabolic Medicine.

DUAL RECEPTOR · SUPERIOR WEIGHT LOSS · DIABETES · HEART HEALTH

Tirzepatide is the world's first **dual GIP and GLP-1 receptor agonist** — a single once-weekly injection that simultaneously activates two of the body's most powerful metabolic hormone pathways. Approved as Mounjaro for type 2 diabetes and Zepbound for obesity, it consistently outperforms semaglutide in head-to-head and comparative data, delivering average weight loss of up to **20.9%** — the highest ever recorded for an approved obesity pharmacotherapy.



~21%

PEAK WEIGHT LOSS

Dual

RECEPTOR ACTION

FDA

APPROVED 2022

Weekly

CONVENIENT DOSING

What Is Tirzepatide?

The science behind the world's first dual incretin receptor agonist


Two Hormones. One Molecule. Breakthrough Results.

Tirzepatide works by mimicking two natural gut hormones simultaneously — **GLP-1** (glucagon-like peptide-1) and **GIP** (glucose-dependent insulintropic polypeptide). While semaglutide activates only the GLP-1 receptor, tirzepatide activates both, amplifying the body's metabolic response across the brain, pancreas, adipose tissue, and gut. This dual mechanism is what drives its superior outcomes in every major clinical comparison to date.

Why GIP Changes Everything

GIP is an often-overlooked incretin hormone that plays a distinct and complementary role to GLP-1. In fat cells, GIP receptor activation promotes fat storage during energy surplus and fat release during energy deficit — improving the body's ability to use fat as fuel. In the brain, GIP amplifies the satiety signals initiated by GLP-1, producing a stronger and more sustained reduction in appetite. Together, the two pathways create a synergistic metabolic effect that neither can achieve alone.

Tirzepatide vs Semaglutide — Head to Head



- GLP-1 Action**
Reduces appetite, slows gastric emptying, and stimulates insulin release — shared with semaglutide.
- GIP Action**
Amplifies fat utilisation and enhances brain satiety signals — unique to tirzepatide.
- Dual Synergy**
The combined effect produces 30–40% greater weight loss than GLP-1 agonism alone.
- Tolerability**
Despite greater efficacy, GI side effects are comparable to or lower than semaglutide at equivalent doses.

★ SURPASS TRIAL PROGRAMME — REWRITING THE STANDARD

The SURMOUNT and SURPASS clinical trial programmes enrolled over 15,000 participants across 10+ global trials. Tirzepatide consistently delivered superior HbA1c reduction, body weight loss, and cardiometabolic improvements compared to all comparator agents — including insulin degludec, dulaglutide, and semaglutide.

The Benefits of Tirzepatide

Dual-receptor power — superior outcomes across every metabolic marker

01 Record-Breaking Weight Loss

At the 15 mg dose, tirzepatide produced average weight loss of 20.9% over 72 weeks in the SURMOUNT-1 trial — with one-third of participants losing more than 25% of their body weight. This is the highest weight loss ever achieved by an approved pharmacotherapy.

02 Superior Blood Sugar Control

In the SURPASS trials, tirzepatide reduced HbA1c by up to 2.58% — significantly exceeding semaglutide and all insulin comparators — while achieving the target HbA1c of below 7% in the majority of participants.



03 Cardiovascular Risk Reduction

The SURPASS-CVOT programme is establishing tirzepatide's cardiovascular benefits. Interim data show significant improvements in blood pressure, LDL cholesterol, triglycerides, and inflammatory markers — consistent with a meaningful reduction in long-term cardiac risk.

04 Dual Appetite Suppression

By activating both GLP-1 and GIP receptors in the hypothalamus, tirzepatide delivers a more powerful and sustained reduction in hunger than GLP-1 agonists alone — making dietary adherence significantly easier for patients.

05 Improved Fat Metabolism

GIP receptor activation specifically improves adipose tissue function — promoting healthier fat distribution, reducing visceral fat preferentially over subcutaneous fat, and improving the metabolic health of fat tissue itself.

06 Liver & Metabolic Health

Clinical data show tirzepatide significantly reduces liver fat, liver enzymes, and markers of NASH — with phase III trials underway confirming its potential as the first approved treatment for non-alcoholic steatohepatitis.

07 Kidney & Renal Protection

Like semaglutide, tirzepatide appears to provide meaningful kidney protection in people with type 2 diabetes and chronic kidney disease — with ongoing trials expected to confirm its cardiorenal benefits.

08 Quality of Life & Mental Wellbeing

Participants in SURMOUNT trials reported dramatic improvements in physical functioning, mobility, sleep quality (including sleep apnea resolution), and emotional wellbeing — with the benefits scaling with the degree of weight lost.

Tirzepatide does not merely improve on semaglutide — it represents a new category of metabolic medicine. With dual-receptor action delivering the greatest weight loss ever recorded for an approved drug, it is redefining what is possible in the treatment of obesity and type 2 diabetes.

Important: Tirzepatide is an FDA-approved prescription medication (Mounjaro / Zepbound). Use only under the supervision of a qualified healthcare professional. Common side effects include nausea, diarrhoea, and vomiting. Not suitable for all patients. Clinical data cited from published SURPASS and SURMOUNT trial results.